LRI Commends GSK as Leader in Sharing Clinical Data
Wednesday, October 17, 2012
The Lupus Research Institute commends GlaxoSmithKline (GSK) for announcing their plans to share all their clinical trial information with the scientific community. For lupus patients, it will give scientists access to a breadth of data to learn more about the results of clinical trials testing the safety and effectiveness of the first treatment for lupus in 50 years, Benlysta.
As noted by many industry commentators, this represents a leadership step in transparency among the pharmaceutical industry.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms